Schrödinger today announced that new preclinical data on SGR-3515 and SGR-4174 will be presented at the AACR Annual Meeting ...

its SOS1 inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25 - 30, 2025 in Chicago, IL. The SGR-3515 presentation will ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two plixorafenib abstracts have been ...

Exelixis, Inc. today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 ...

including pancreatic and colorectal cancer - and SOS1 inhibitor MRTX0902, designed to boost the activity of KRAS-targeting drugs. “With multiple targeted oncology assets including Krazati ...

If a deal was forthcoming, the buyer would also claim a pipeline of follow-up cancer drugs including TAM ... and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported ...

As such, pan-RAS inhibitors, and inhibitors of SOS1 are being developed that show promise in preclinical ... novel RAS-targeted inhibitors for the treatment and hopefully cure of cancer. We are ...

Mar. 18, 2025 — Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

Are you putting too much pressure on yourself? Or chasing after other people’s idea of career success? Get back in touch with what drives YOU today, Cancer.

Mar. 18, 2025 — Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...